RxDoctor Payments DataLook up a doctor →

Donna Draper

Psychiatric/Mental Health · Danbury, CTNPI 1912212358

Payments from drug & device makers

$19,191in general payments, 2019–2025

Across 841 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Neurocrine Biosciences, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $7K from 27 others

What the payments were for

  • Food & beverage$19,01399%
  • Education$1781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,191 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$37,658
Medicare patients
49
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide14$10,127
Bupropion XlBupropion Hcl117$2,839
Lurasidone Hcl18$2,527
Aripiprazole56$2,522
Duloxetine Hcl106$2,407
Methylphenidate ErMethylphenidate Hcl12$1,346
Hydroxyzine Hcl13$1,292
Venlafaxine Hcl ErVenlafaxine Hcl41$1,161
Trazodone Hcl73$989
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl11$966
Mirtazapine35$813
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$807
Quetiapine Fumarate27$746
Clonazepam77$679
Methylphenidate Hcl26$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,240$10,12714 claims
Almatica Pharma LLCSertraline Hcl$104$54567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →